Building the Case for Clopidogrel as a World Health Organization Essential Medicine

Circulation: Cardiovascular Quality and Outcomes

Volumn 8, Issue 4, 2015, Pages 447-451

  Patel, Amisha ^a   Vidula, Mahesh ^b   Kishore, Sunny P ^c,d   Vedanthan, Rajesh ^e   Huffman, Mark D ^a  

^a Departments of Preventive Medicine and Behavioral Sciences   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Young Professionals Chronic Disease Network   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

clopidogrel; drugs; essential; World Health Organization

Indexed keywords

ACETYLSALICYLIC ACID; BISOPROLOL; CLOPIDOGREL; DIPYRIDAMOLE; HEPARIN; PRASUGREL; SIMVASTATIN; STREPTOKINASE; TICAGRELOR; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; ESSENTIAL DRUG;

ACUTE CORONARY SYNDROME; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY RECANALIZATION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG INDUSTRY; DRUG SAFETY; EMERGENCY CARE; EVIDENCE BASED PRACTICE; GASTROINTESTINAL HEMORRHAGE; GROSS NATIONAL PRODUCT; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH CARE PLANNING; HEART CATHETERIZATION; HUMAN; INDIGESTION; INTENSIVE CARE; ISCHEMIC HEART DISEASE; MONOTHERAPY; NAUSEA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREMATURE MORTALITY; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; REVIEW; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW (TOPIC); TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; VOMITING; WORLD HEALTH ORGANIZATION; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; DRUG UTILIZATION; HEALTH CARE POLICY;

CARDIOVASCULAR DISEASES; DRUG UTILIZATION; DRUGS, ESSENTIAL; HEALTH POLICY; HUMANS; PLATELET AGGREGATION INHIBITORS; PUBLIC HEALTH; TICLOPIDINE; WORLD HEALTH ORGANIZATION;

EID: 84937676024     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.115.001866     Document Type: Review

References (50)

1. Reidenberg MM. Essential medicines for the whole world. Clin Pharmacol Ther. 2007; 82: 500-503. doi: 10.1038/sj.clpt.6100388.
2. Quick JD, Hogerzeil HV, Velasquez G, Rago L. Twenty-five years of essential medicines. Bull World Health Organ. 2002; 80: 913-914.
3. Kishore SP, Vedanthan R, Fuster V. Promoting global cardiovascular health ensuring access to essential cardiovascular medicines in low-and middle-income countries. J Am Coll Cardiol. 2011; 57: 1980-1987. doi: 10.1016/j.jacc.2010.12.029.
4. Levison L LR. The hidden costs of essential medicines. Essential Drugs Monitor. 2003; 33: 20-21.
5. Vialle-Valentin CE, Ross-Degnan D, Ntaganira J, Wagner AK. Medicines coverage and community-based health insurance in low-income countries. Health Res Policy Syst. 2008; 6: 11. doi: 10.1186/1478-4505-6-11.
6. WHO Member States make progress on noncommunicable diseases. http://www.who.int/mediacentre/news/notes/2012/ncd-20121109/en/. Accessed March 16, 2015.
7. WHO 18th Model List of Essential Medicines. http://www.who.int/medicines/publications/essentialmedicines/18th-EML-Final-web-8Jul13.pdf. Accessed March 16, 2015.
8. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl-No=020839&TABLE1=OB-Rx. Accessed March 16, 2015.
9. Preliminary Injunction Against Apotex Upheld on Appeal. http://www.prnewswire.com/news-releases/preliminary-injunction-against-apotexupheld-on-appeal-56053592.html. Accessed March 16, 2015.
10. Pierson R, Bansal P. U.S. judge upholds Bristol, Sanofi patent on Plavix. http://www.reuters.com/article/2007/06/19/us-bristolmyers-plavix-patent-idUSN1931607820070619. Accessed March 16, 2015.
11. FDA approves generic versions of blood thinner Plavix. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm304489.htm. Accessed March 16, 2015.
12. European Medicines Agency. Clopidogrel Acino. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001166/human-med-000702.jsp&mid=WC0b01ac058001d124. Accessed March 16, 2015.
13. Mohara A, Yamabhai I, Chaisiri K, Tantivess S, Teerawattananon Y. Impact of the introduction of government use licenses on the drug expenditure on seven medicines in Thailand. Value Health. 2012; 15(1 Suppl): S95-S99. doi: 10.1016/j.jval.2011.11.016.
14. Steinbrook R. Closing the affordability gap for drugs in low-income countries. N Engl J Med. 2007; 357: 1996-1999. doi: 10.1056/NEJMp0706918.
15. Yamabhai I, Mohara A, Tantivess S, Chaisiri K, Teerawattananon Y. Government use licenses in Thailand: an assessment of the health and economic impacts. Global Health. 2011; 7: 28. doi: 10.1186/1744-8603-7-28.
16. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2095-2128. doi: 10.1016/S0140-6736(12)61728-0.
17. Joshi R, Jan S, Wu Y, MacMahon S. Global inequalities in access to cardiovascular health care: our greatest challenge. J Am Coll Cardiol. 2008; 52: 1817-1825. doi: 10.1016/j.jacc.2008.08.049.
18. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3: e442. doi: 10.1371/journal. pmed.0030442.
19. Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S. The Global Economic Burden of Non-Communicable Diseases. 2011. Geneva: World Economic Forum; 2012.
20. de Vreede JJ, Gorgels AP, Verstraaten GM, Vermeer F, Dassen WR, Wellens HJ. Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis. J Am Coll Cardiol. 1991; 18: 698-706.
21. Flynn A, Moscucci M, Share D, Smith D, LaLonde T, Changezi H, Riba A, Gurm HS. Trends in door-to-balloon time and mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Arch Intern Med. 2010; 170: 1842-1849. doi: 10.1001/archinternmed.2010.381.
22. Gillum RF. Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol. 1994; 23: 1273-1277.
23. Krumholz HM, Normand SL, Wang Y. Trends in hospitalizations and outcomes for acute cardiovascular disease and stroke, 1999-2011. Circulation. 2014; 130: 966-975. doi: 10.1161/CIRCULATIONAHA.113.007787.
24. Huffman MD, Prabhakaran D, Abraham AK, Krishnan MN, Nambiar AC, Mohanan PP; Kerala Acute Coronary Syndrome Registry Investigators. Optimal in-hospital and discharge medical therapy in acute coronary syndromes in Kerala: results from the Kerala acute coronary syndrome registry. Circ Cardiovasc Qual Outcomes. 2013; 6: 436-443. doi: 10.1161/CIRCOUTCOMES.113.000189.
25. Karthikeyan G, Xavier D, Prabhakaran D, Pais P. Perspectives on the management of coronary artery disease in India. Heart. 2007; 93: 1334-1338. doi: 10.1136/hrt.2007.131193.
26. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011; 378: 1231-1243. doi: 10.1016/S0140-6736(11)61215-4.
27. Kaul U, Bhatia V. Perspective on coronary interventions & cardiac surgeries in India. Indian J Med Res. 2010; 132: 543-548.
28. Ramakrishnan S, Mishra S, Chakraborty R, Chandra KS, Mardikar HM. The report on the Indian coronary intervention data for the year 2011-National Interventional Council. Indian Heart J. 2013; 65: 518-521. doi: 10.1016/j.ihj.2013.08.009.
29. Gao R. Current status of percutaneous coronary intervention in China. Heart. 2010; 96: 415-418. doi: 10.1136/hrt.2009.170571.
30. Huo Y. Current status and development of percutaneous coronary intervention in China. J Zhejiang Univ Sci B. 2010; 11: 631-633. doi: 10.1631/jzus.B1001012.
31. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130: 2354-2394. doi: 10.1161/CIR.0000000000000133.
32. O'Gara PT, Kushner FG, Ascheim DD, Casey DEJ, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61: e78-140.
33. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with STsegment elevation. N Engl J Med. 2005; 352: 1179-1189. doi: 10.1056/NEJMoa050522.
34. Shimony A, Grandi SM, Pilote L, Joseph L, O'Loughlin J, Paradis G, Rinfret S, Sarrafzadegan N, Adamjee N, Yadav R, Gamra H, Diodati JG, Eisenberg MJ; ZESCA Investigators. Utilization of evidence-based therapy for acute coronary syndrome in high-income and low/middleincome countries. Am J Cardiol. 2014; 113: 793-797. doi: 10.1016/j. amjcard.2013.11.024.
35. Huffman MD, Yusuf S. Polypills: essential medicines for cardiovascular disease secondary prevention? J Am Coll Cardiol. 2014; 63: 1368-1370. doi: 10.1016/j.jacc.2013.08.1665.
36. Berg J, Lindgren P, Spiesser J, Parry D, Jönsson B. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials. Clin Ther. 2007; 29: 1184-1202. doi: 10.1016/j.clinthera.2007.06.020.
37. Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol. 2008; 101: 960-966. doi: 10.1016/j.amjcard.2007.11.057.
38. Weintraub WS, Mandel L, Weiss SA. Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations. Pharmacoeconomics. 2013; 31: 959-970. doi: 10.1007/s40273-013-0088-8.
39. Zhang Z, Kolm P, Mosse F, Jackson J, Zhao L, Weintraub WS. Longterm cost-effectiveness of clopidogrel in STEMI patients. Int J Cardiol. 2009; 135: 353-360. doi: 10.1016/j.ijcard.2008.04.011.
40. Bellemain-Appaix A, O'Connor SA, Silvain J, Cucherat M, Beygui F, Barthélémy O, Collet JP, Jacq L, Bernasconi F, Montalescot G; ACTION Group. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA. 2012; 308: 2507-2516. doi: 10.1001/jama.2012.50788.
41. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005; 294: 1224-1232. doi: 10.1001/jama.294.10.1224.
42. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502. doi: 10.1056/NEJMoa010746.
43. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348: 1329-1339.
44. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45: 2160-2236. doi: 10.1161/STR.0000000000000024.
45. Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med. 1998; 3: 257-260.
46. Beinart SC, Kolm P, Veledar E, Zhang Z, Mahoney EM, Bouin O, Gabriel S, Jackson J, Chen R, Caro J, Steinhubl S, Topol E, Weintraub WS. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol. 2005; 46: 761-769. doi: 10.1016/j.jacc.2005.03.073.
47. Cost effectiveness and strategic planning (WHO CHOICE). http://www.who.int/choice/costs/CER-thresholds/en/. Accessed March 17, 2015.
48. Management Sciences for Health. International Drug Price Indicator Guide. 2013. http://erc.msh.org/dmpguide/pdf/DrugPriceGuide-2013-en.pdf. Accessed March 17, 2015.
49. International Monetary Fund. World Economic Outlook Database. 2013. http://www.imf.org/external/pubs/ft/weo/2013/02/weodata/index.aspx. Accessed March 17, 2015.
50. WHO 19th Model List of Essential Medicines. http://www.who.int/medicines/publications/essentialmedicines/EML2015-8-May-15.pdf. Accessed May 11, 2015.